Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

The Safety and Performence of ShockPulse-10 in Patients with Coronary Artery Calcification

NCT06711822 · tracked via the Priya Life Science China tracker
Sponsor
Keya Medical
Phase
Not applicable
Started
2024-07-01
Last updated
2024-12-02

Condition(s) studied

Coronary Arterial Disease (CAD)Calcification; Heart

Investigational drug(s) / intervention(s)

Shockplus-10

Shockplus-10: Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of ShockPulse-10 treatment by their physicians

Study summary

This study is an exploratory, multicenter, single-group clinical trial aimed to evaluate the clinical outcomes of using ShockPulse-10 in the treatment of coronary artery calcification .

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: 1. Patient is ≥ 18 years of age; 2. Patients with significant coronary artery disease (including stable or unstable angina and asymptomatic myocardial ischemia) who are suitable for PCI treatment; 3. A single newly developed stenosis of the target vessel, which is the left anterior descending artery, right coronary artery, or circumflex artery (or its branches), with stenosis degree ≥70% or ≥50% (Visually inspect ) and accompanied by evidence of ischemia; 4. The target lesion is a primary, in situ coronary artery lesion; 5. The reference vessel diameter for the target lesion is 2.0-4.0mm, and the length of the target lesion is ≤40mm (Visually inspect); 6. Visual assessment indicates that the lesion site can accommodate the passage of a pre-dilator or trial instrument through the lesion; 7. The target lesion site has moderate to severe calcification (meeting one of the following conditions): ① Angiography: Moderate calcification :clearer and more easily visible high-density shadows during cardiac pulsation; Severe calcification :clear high-density shadows both during and at rest; ② IVUS calcium score ≥2 points for superficial intimal, deep medial, and mixed calcification; 8. TIMI grade 3 in target vessel before registration (pre-dilation is allowed); Key exclusion Criteria: 1. Left ventricular ejection fraction \< 40%; 2. NYHA class III or IV heart failure; 3. Patients with single coronary artery supply; 4. Patients with evidence of dissection at the site of the lesion on imaging; 5. The imaging suggests that the vascular pathway is tortuous, making it difficult for the pre-dilatation device to reach the target location or to be retrieved; 6. Patients with active systemic infections; 7. Patients with uncontrollable severe hypertension (systolic pressure \> 180 mmHg or diastolic pressure \> 110 mmHg); 8. Patients with coagulopathy, hypercoagulable state or significant bleeding tendency (hemoglobin \<10g/dL or platelet count \<80×10\^9/L);

Primary outcome measure(s)

  • Procedure success — immediately post-procedure or prior to discharge, whichever comes first
    Procedure success defined as successful stent implantation, residual stenosis degree ≤30% , and no major adverse cardiac events (MACE) occurring during hospitalization
  • Freedom from major adverse cardiac events (MACE) within 30 days of the index procedure — 30(±7days)days post index procedure
    Freedom from major adverse cardiac events (MACE) within 30(±7days) days of the index procedure;MACE is defined as:Cardiac death; or Myocardial Infarction (MI): or Target Vessel Revascularization

Trial sites (1)

FacilityCityRegionStatus
Beijing Anzhen Hosipital Beijing Beijing Municipality Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06711822 on ClinicalTrials.gov ↗ ← All trials in China